At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 224 enrolled
Drug / intervention
Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
In Brief
A Phase 3 clinical trial evaluating Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation for Coronary Artery Disease. Completed, enrolled 224 participants across 28 sites.
Detailed Summary
The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to \< 2.75 mm diameter.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartJul 2007
Primary CompletionJun 2009
Study CompletionOct 2013
TodayJul 2026
First PostedJun 21, 2007
Enrollment StartJul 1, 2007
Primary CompletionJun 1, 2009
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.0 years ago
Interventions
Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantationdevice
TAXUS Element stent implantation